T
Thermalin Diabetes
Developing next-generation, heat-stable, and rapid-acting insulin analogs
About Thermalin Diabetes
Thermalin Diabetes, LLC is a biotechnology firm founded in 2007, operating out of Cleveland, Ohio. The company focuses on developing a portfolio of next-generation insulin analogs to address unmet needs in the diabetes market. Its product pipeline includes ultra-stable insulins that do not require refrigeration, ultra-rapid absorbing insulins for artificial pancreas systems, ultra-concentrated formulas for miniaturized insulin pumps, and liver-focused insulins for active diabetic patients.
The company was founded by Dr. Michael A. Weiss, a distinguished researcher from Case Western Reserve University (CWRU) School of Medicine, who has studied insulin for over three decades. His scientific work on engineering new insulin molecules forms the basis of the company's intellectual property, which is exclusively licensed from CWRU. The business side was initially led by CEO Rick Berenson, a serial entrepreneur and a former Harvard undergraduate roommate of Dr. Weiss. The company's business model revolves around research and development, with the goal of forming strategic partnerships with large pharmaceutical companies for clinical development and commercialization. A significant milestone was a major collaboration with Sanofi announced in 2017 to discover and develop novel insulin therapies, which included a Series A financing round of at least $17.5 million.
Thermalin has secured substantial funding through multiple rounds, raising over $56 million from investors like Sanofi, Jumpstart, and JSR・mblVC LifeScience Investment Limited Partnership, in addition to grants from the National Institutes of Health (NIH). The company's strategy is to create superior insulin products that are faster-acting, longer-lasting, more concentrated, and more stable than existing options, aiming to reduce the burden of insulin therapy, improve patient adherence, and enhance safety.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 6
- Open positions
- None listed
- Dealroom signal
- 25.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Personal Health, Diabetes, Biotechnology, Cardiology and cardiovascular, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| OtherOther financing | Aug 2022 | $0 | — | Robin Hood Ventures | — |
| CONVERTIBLEEquity / VC | Sep 2020 | $45K | — | Undisclosed | — |
Growth signals
Latest recorded traffic for Thermalin Diabetes is 250 monthly website visits, down 55.4% over the last three months. Thermalin Diabetes's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Thermalin Diabetes in the Cleveland ecosystem
The Thermalin Diabetes office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
JumpStart Ventures
U.S. Small Business Administration
US Department of Health and Human Services
National Institutes of Health
Series A3 investors entered at this stage
Sanofi
Green Park & Golf Ventures
JumpStart
Other known investors7 additional known investors
Case Western Reserve University- RVRobin Hood Ventures
Innovation Fund Northeast Ohio- KHKensington Capital Holdings
- MAMass Medical Angels
Mid Atlantic Bio Angels
Small Business Innovation Research
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Thermalin Diabetes on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Thermalin Diabetes’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









